Updated:
LEO Pharma A/S
LEO Pharma was established in 1908 by pharmacist August Kongsted and his son-in-law Anton Antons, initially focusing on skin treatments. The company is wholly...
LEO Pharma A/S
LEO Pharma was established in 1908 by pharmacist August Kongsted and his son-in-law Anton Antons, initially focusing on skin treatments. The company is wholly owned by the LEO Foundation, a Danish philanthropic foundation, which provides a stable long-term ownership structure similar to a single-family office. LEO Pharma's strategic direction is set by a board appointed by the foundation, with profits partly reinvested and partly distributed to charitable causes. The company operates exclusively in dermatology, with a portfolio covering psoriasis, eczema, skin infections, and mycosis. Its R&D pipeline includes biologics and topical therapies, with key products including Enstilar, Taclonex, and the newer biologic tralokinumab (Adtralza). LEO Pharma has commercial presence in over 100 countries, with major markets in Europe, North America, and Asia (per the firm's annual report, 2023). The firm has expanded through acquisitions, including its 2021 purchase of the dermatology business of Bayer's prescription medicine division. As a private foundation-owned entity, LEO Pharma does not publicly disclose AUM or investment returns. The LEO Foundation manages the company's shares and distributes funds to research and humanitarian causes. The firm employs approximately 4,500 people globally, with headquarters near Copenhagen, Denmark (per public record, 2024). A recent operational event of note: LEO Pharma sold its commercial dermatology products in China to the local firm Prinx in 2023, refocusing its pipeline. LEO Pharma's structural differentiator is its foundation ownership, which insulates the company from short-term shareholder pressure. This allows the firm to focus on long-term R&D in a narrow therapeutic area, with profits channeled back into dermatology innovation rather than quarterly earnings targets. The LEO Foundation's charitable mission also creates a distinct governance model uncommon among pharmaceutical firms.
General information
Firm type
null
Year founded
1908
AUM
Undisclosed
Location
Region
Europe
Country
Denmark
City
Ballerup
Corporate office
Ballerup, Denmark
Sector focus
Frequently asked questions
Who owns LEO Pharma?
LEO Pharma is wholly owned by the LEO Foundation, a Danish philanthropic foundation established in 1984. The foundation holds all shares and distributes profits to charitable causes, including dermatological research and humanitarian projects. This structure gives LEO Pharma a long-term ownership horizon similar to a single-family office.
What is LEO Pharma's investment strategy?
LEO Pharma is a commercial pharmaceutical company, not a traditional investment vehicle. It reinvests profits from its dermatology product sales into R&D, acquisitions, and pipeline development. The company's strategy is to focus exclusively on skin health, targeting both topical treatments and biologic therapies.
Does LEO Pharma have a family-office structure?
No, LEO Pharma is a public limited company owned by the LEO Foundation. However, its ownership structure functions like a family office in that the foundation acts as a long-term, private owner with no external shareholders. The foundation's board oversees the company's governance and philanthropic distributions.
What are LEO Pharma's key therapeutic areas?
LEO Pharma focuses on dermatology, with key therapeutic areas including psoriasis (both plaque and guttate), atopic dermatitis (eczema), skin infections, mycosis, and other chronic skin conditions. Its portfolio includes topical corticosteroids, vitamin D analogs, and biologic therapies like tralokinumab (Adtralza).
Where is LEO Pharma headquartered and what is its geographic reach?
LEO Pharma is headquartered in Ballerup, Denmark. It operates in over 100 countries, with major commercial presences in Europe, North America (primarily the United States), and parts of Asia. In 2023, the company sold its commercial operations in China but continues to develop its pipeline for global markets.
How does the LEO Foundation influence LEO Pharma?
The LEO Foundation appoints the board of LEO Pharma and receives dividends from the company's profits. The foundation uses these funds for philanthropic grants supporting dermatological research, education, and humanitarian aid. This creates a feedback loop where commercial success funds public-good initiatives.
Has LEO Pharma made any major acquisitions or divestitures recently?
In 2021, LEO Pharma acquired the dermatology business of Bayer's prescription medicine division, expanding its portfolio. In 2023, it sold its commercial dermatology products in China to Prinx, refocusing on pipeline development in the region. These moves reflect a shift toward a more concentrated R&D strategy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: